BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30114333)

  • 1. The prognostic value of serum thyroid-stimulating hormone level post-lobectomy in low- and intermediate-risk papillary thyroid carcinoma.
    Park JH; Lee YM; Lee YH; Hong SJ; Yoon JH
    J Surg Oncol; 2018 Sep; 118(3):390-396. PubMed ID: 30114333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma.
    Xia Q; Dong S; Bian PD; Wang J; Li CJ
    Eur Arch Otorhinolaryngol; 2016 Apr; 273(4):1037-43. PubMed ID: 25744048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck.
    Lee CW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Jan; 22(1):117-24. PubMed ID: 25034816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for recurrence after therapeutic lateral neck dissection for primary papillary thyroid cancer.
    Kim SJ; Park SY; Lee YJ; Lee EK; Kim SK; Kim TH; Jung YS; Ryu J; Myong JP; Chung KW
    Ann Surg Oncol; 2014 Jun; 21(6):1884-90. PubMed ID: 24515566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robot-assisted Sistrunk's operation, total thyroidectomy, and neck dissection via a transaxillary and retroauricular (TARA) approach in papillary carcinoma arising in thyroglossal duct cyst and thyroid gland.
    Byeon HK; Ban MJ; Lee JM; Ha JG; Kim ES; Koh YW; Choi EC
    Ann Surg Oncol; 2012 Dec; 19(13):4259-61. PubMed ID: 23070784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobectomy is a more Cost-Effective Option than Total Thyroidectomy for 1 to 4 cm Papillary Thyroid Carcinoma that do not Possess Clinically Recognizable High-Risk Features.
    Lang BH; Wong CKH
    Ann Surg Oncol; 2016 Oct; 23(11):3641-3652. PubMed ID: 27221359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
    Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
    Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Robotic total thyroidectomy with modified radical neck dissection via unilateral retroauricular approach.
    Byeon HK; Holsinger FC; Tufano RP; Chung HJ; Kim WS; Koh YW; Choi EC
    Ann Surg Oncol; 2014 Nov; 21(12):3872-5. PubMed ID: 25227305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer recurrence in papillary thyroid microcarcinoma: a multivariate analysis on 231 patients with a 12-year follow-up.
    Pedrazzini L; Baroli A; Marzoli L; Guglielmi R; Papini E
    Minerva Endocrinol; 2013 Sep; 38(3):269-79. PubMed ID: 24126547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.
    Park S; Jeon MJ; Oh HS; Lee YM; Sung TY; Han M; Han JM; Kim TY; Chung KW; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Aug; 28(8):997-1003. PubMed ID: 29845894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postoperative Thyroid-Stimulating Hormone Levels Did Not Affect Recurrence after Thyroid Lobectomy in Patients with Papillary Thyroid Cancer.
    Lee MC; Kim MJ; Choi HS; Cho SW; Lee GH; Park YJ; Park DJ
    Endocrinol Metab (Seoul); 2019 Jun; 34(2):150-157. PubMed ID: 31099202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma.
    Ernaga-Lorea A; Hernández-Morhain MC; Anda-Apiñániz E; Pineda-Arribas JJ; Migueliz-Bermejo I; Eguílaz-Esparza N; Irigaray-Echarri A
    Clin Transl Oncol; 2018 Jun; 20(6):740-744. PubMed ID: 29071517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of association between high serum thyroid-stimulating hormone level and risk of papillary thyroid microcarcinomas.
    Sohn SY; Kim HJ; Jang HW; Kim SW; Chung JH
    Head Neck; 2014 Jan; 36(1):43-6. PubMed ID: 23728859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid stimulating hormone suppression and recurrence after thyroid lobectomy for papillary thyroid carcinoma.
    Bae MR; Nam SH; Roh JL; Choi SH; Nam SY; Kim SY
    Endocrine; 2022 Feb; 75(2):487-494. PubMed ID: 34689317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node ratio of the central compartment is a significant predictor for locoregional recurrence after prophylactic central neck dissection in patients with thyroid papillary carcinoma.
    Ryu IS; Song CI; Choi SH; Roh JL; Nam SY; Kim SY
    Ann Surg Oncol; 2014 Jan; 21(1):277-83. PubMed ID: 24006096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma.
    Gao Y; Qu N; Zhang L; Chen JY; Ji QH
    Tumour Biol; 2016 Jun; 37(6):7453-9. PubMed ID: 26678888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.
    Sondermann A; Andreghetto FM; Moulatlet AC; da Silva Victor E; de Castro MG; Nunes FD; Brandão LG; Severino P
    Clin Exp Metastasis; 2015 Aug; 32(6):521-30. PubMed ID: 26007293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High recurrent rate of multicentric papillary thyroid carcinoma.
    Lin JD; Chao TC; Hsueh C; Kuo SF
    Ann Surg Oncol; 2009 Sep; 16(9):2609-16. PubMed ID: 19533244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Na YM; Cho JS; Park MH
    Anticancer Res; 2021 Nov; 41(11):5713-5721. PubMed ID: 34732444
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.